661 results about "Pain duration" patented technology

Methods and compositions for the treatment of conditions including ocular, stress-associated, and neurodegenerative conditions in a mammal using a composition which directly or indirectly stimulates alpha 2 adrenoreceptor agonist activity with a minimum of sedation or other side effects.

Microneedle devices with microneedles having a truncated tapered shape are disclosed. The microneedles of microneedle devices may also have a controlled aspect ratio. Microneedle delivery apparatus are disclosed that include drivers designed to deliver microneedles at velocities that may enhance perforation of the stratum corneum while limiting the sensation of pain experienced at the delivery site.

An implantable neurostimulator system for treating pain includes scheduled and responsive therapy capabilities including responsive stimulation applied to the brain and peripheral sections of the nervous system. Methods for treating chronic nociceptive, neuropathic, and psychogenic pain employ an inventive system to advantageously reduce multiple symptoms and components of pain and to address underlying causes of pain.

A novel medical probe assembly, system, and methods for the use thereof to treat tissue are described. The system optionally comprises an energy source, two probe assemblies, and one or more cooling devices to provide cooling to at least one of the probe assemblies. The probe assemblies may be configured in a bipolar mode, whereby current flows preferentially between the probe assemblies. The probe assemblies and system described herein are particularly useful to deliver radio frequency energy to a patient's body. RF energy delivery may be used for various applications, including the treatment of pain, tumor ablation and cardiac ablation.

A flexible medical intubation instrument provided for placement into an animal or human patient comprises a catheter with at least a pair of longitudinally extending lumens or channels including a sensor and/or actuator channel and a working channel. In the sensor/actuator channel is provided a fixed or slideably removable sensor cable having a sensor for sensing a characteristic or condition including any of the following: a visual sensor for optical viewing, a chemical sensor, a pH sensor, a pressure sensor, an infection sensor, an audio sensor, or a temperature sensor. The sensors are coupled by the sensor/actuator cable through light transmission, electric current, or radio transmission to a viewing instrument or other output device such as a meter or video screen for displaying the condition that is sensed within the body of the patient while the flexibility of the composite structure comprising the catheter and cable enable the entire instrument to flex laterally as it moves through curved passages or around obstructions during insertion or removal. While making observations through the sensor channel, the working channel simultaneously functions as a drain or an irrigation duct, a feeding tube, or to provide a passage for the insertion of one or a succession of surgical devices such that the catheter serves as a protective artificial tract or liner as surgical devices are inserted and removed through it in succession so as to minimize tissue trauma, infection, and pain experienced by the patient. The instrument can be used in urology, as well as a visually directed nasogastric tube, as a visually directed external gastrostomy tube, or as a visually directed internal gastric tube or percutaneous endoscopic gastrostomy tube and in other applications.

The present invention provides capsaicinoid gel formulations and methods for relieving pre- and post-surgical pain at a site in a human or animal by administering at a surgical site in a human or animal in need thereof a dose of capsaicinoid gel in an amount effective to attenuate post-surgical pain at the surgical site, the dose of capsaicin ranging from 100 μg to 10,000 μg.

The present invention relates to an administration instrument for medical use that can perform injection of a drug solution with stability and with great reliability. For example, at the administration, it is possible to prevent a force that presses the injection button from acting in a direction of inserting the needle that is inserted into the skin deeper, and enables the administration under a stable state where the needle does not wobble, thereby alleviating physical and mental pain of the administration patient.

With a structure in which an injection button (3) is pressed at an angle that is not parallel to the needle with respect to a direction in which the needle (4) is inserted into the skin, it is possible to prevent the force of pressing the injection button from being transmitted in a direction of inserting the needle into the skin deeper than the initial insertion of the needle, thereby achieving an administration under a stable state.

The invention relates to a custom-fitting, asymmetric ballet shoe with a shell (9) and liner (13) that enables the dancer to stand en pointe and perform the extreme movements required by ballet choreography with minimal discomfort, pain, and injury to the foot caused by the various aerial ballet maneuvers called for by both traditional and modern choreography. The shoe of the present invention is designed to redistribute the dancer's weight and the ground force reactions associated with dancing en pointe evenly across the toes while translating some of the force away from the distal aspect of the dancer's toes to the rest of the foot. The shoe has a removable cosmetic cover (18) to enable, inter alia, the color and design to be varied according to costume design and the cover's replacement when the fabric is worn, thereby extending the useful life of the remainder of the shoe.

An apparatus adapted to inhibit pain signals generated by pain receptors in the skin during a skin related medical treatment such as an injection. An evacuation chamber is provided with an essentially rigid interface element larger than a threshold surface area through which a medical treatment can be administered to a selected skin region, one or more walls which are placeable in the vicinity of the skin region, an interior defined by the walls and by the interface element, and an opening at the bottom of the interior which is sealable by the skin region. A device generates a vacuum within the evacuation chamber interior to a level greater than the threshold vacuum level suitable for drawing the skin region through the opening towards, and in a compressing relation against, the interface element, to inhibit the transmission of a pain signal generated by pain receptors located within the skin region.

Methods of treating, preventing and/or managing dysfunctional sleep, including but not limited to, dysfunctional sleep associated with chronic neurological or inflammatory condition such as pain and neurodegenerative disorders, which comprise the administration of one or more immunomodulatory compounds or a pharmaceutically acceptable salt, solvate, stereoisomer, clathrate or prodrug thereof, alone or in combination with known therapeutics are disclosed. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.

A medical probe assembly, system, and methods for the use thereof to treat tissue are described. The system optionally comprises an energy source, two internally-cooled probe assemblies, and one or more cooling devices to provide cooling to at least one of the probe assemblies. The probe assemblies may be configured in a bipolar mode, whereby current flows preferentially between the probe assemblies. The probe assemblies and system described herein are particularly useful to deliver radio frequency energy to a patient's body. RF energy delivery may be used for various applications, including the treatment of pain, tumor ablation and cardiac ablation.

The delivery of biopharmaceutical and other therapeutic agents parenterally to an animal via a minimally invasive, low pain administration is provided. The agents are delivered to the patient via, e.g., the epidermal, dermal, or subcutaneous layer of the skin in a concentrated form of injectable paste of slurry.

The present invention relates generally to medical measurement systems for evaluation of organ function and understanding symptom and pain mechanisms. This model takes into account a number of factors such as volume and properties of the fluid and the surrounding tissue. Particular emphasis is on a multifunctional probe that can provide a number of measurements including volume of refluxate in the esophagus and to what level it extents. The preferred embodiments of the invention relate to methods and apparatus for measuring luminal cross-sectional areas of internal organs such as blood vessels, the gastrointestinal tract, the urogenital tract and other hollow visceral organs and the volume of the flow through the organ. It can also be used to determine conductivity of the fluid in the lumen and thereby it can determine the parallel conductance of the wall and geometric and mechanical properties of the organ wall.

This invention relates to a method for the biochemical treatment of persistent pain disorders by inhibiting the biochemical mediators of inflammation in a subject comprising administering to said subject any one of several combinations of components that are inhibitors of biochemical mediators of inflammation. Said process for biochemical treatment of persistent pain disorders is based on Sota Omoigui's Law, which states: ‘The origin of all pain is inflammation and the inflammatory response’. Sota Omoigui's Law of Pain unifies all pain syndromes as sharing a common origin of inflammation and the inflammatory response. The various biochemical mediators of inflammation are present in differing amounts in all pain syndromes and are responsible for the pain experience. Classification and treatment of pain syndromes should depend on the complex inflammatory profile. A variety of mediators are generated by tissue injury and inflammation. These include substances produced by damaged tissue, substances of vascular origin as well as substances released by nerve fibers themselves, sympathetic fibers and various immune cells. Biochemical mediators of inflammation that are targeted for inhibition include but are not limited to: prostaglandin, nitric oxide, tumor necrosis factor alpha, interleukin 1-alpha, interleukin 1-beta, interleukin-4, Interleukin-6 and interleukin-8, histamine and serotonin, substance P, Matrix Metallo-Proteinase, calcitonin gene-related peptide, vasoactive intestinal peptide as well as the potent inflammatory mediator peptide proteins neurokinin A, bradykinin, kallidin and T-kinin.

Compounds of formula 1 are modulators of P2X3 useful for the treatment of pain and genito-urinary, gastrointestinal, and respiratory disorders:

wherein

• • R¹ is —C(═S)CH₃, pyridyl, pyrimidinyl, pyrazinyl, thiazolyl, furyl, furylcarbonyl, acetyl, or carbamoyl; R^2a and R^2b are independently H, methyl, or ethyl; R³ is H or methyl; Y is a bond, —(CR⁴R⁵)_n— or —CR⁴═CR⁵—; wherein R⁴ and R⁵ are each independently H or methyl and n is 1 or 2; X is N or CH; A is phenyl, 5-membered heterocyclyl, or 6-membered heterocyclyl; R⁶, R⁷ and R⁸ are each independently H, halo, lower alkyl, cycloalkyl, alkylthio, alkylthio-lower alkyl, alkylsulfonyl-lower alkyl, di(lower alkyl)amino-lower alkyl, morpholinyl-lower alkyl, 4-methyl-piperazinyl-methyl, trifluoromethyl, pyridyl, tetrazolyl, thiophenyl, phenyl, biphenyl, or benzyl (where thiophenyl, phenyl and benzyl are substituted with 0-3 lower alkyl, halo, sulfonamido, trifluoromethyl, lower alkoxy or lower alkylthio) or R⁶ and R⁷ together form a 5-membered or 6-membered carbocyclic or heterocyclic ring substituted with 0-3 substituents selected from the group consisting of lower alkyl, lower alkoxy, oxo, halo, thiophenyl-lower alkyl, phenyl, benzyl (where phenyl and benzyl are substituted with 0-3 lower alkyl, halo, sulfonamido, trifluoro-methyl, lower alkoxy, lower alkylthio, amino-lower alkyl, lower alkylamino-lower alkyl, or di(lower alkyl)amino-lower alkyl); and pharmaceutically acceptable salts thereof; wherein when R¹ is pyrimidin-2-yl, X is N, Y is a bond and A is oxazol-5-yl the carbon atom at position 4 in said oxazol-5-yl is not substituted by propyl when the carbon atom at position 2 in said oxazol-5-yl is substituted by substituted phenyl and the carbon atom at position 4 in said oxazol-5-yl is not substituted by phenyl when the carbon atom at position 2 is substituted by unsubstituted or substituted phenyl.

Devices and methods for utilizing electromagnetic radiation and other forms of energy to treat a volume of tissue at depth are described. In one aspect, a device modulates the flux incident on surface tissue to control and vary the depth in the tissue at which an effective dose of radiant energy is delivered and, thereby, treat a specific volume of tissue. The methods and devices disclosed are used to perform various treatments, including treatments to prevent and relieve pain and promote healing of tissue.

A method is disclosed for electrically stimulating a cranial nerve, especially a vagus nerve, to treat or alleviate angina pectoris. Pain is lessened or prevented by application of predetermined therapeutic electrical signal to a selected location on the cranial nerve of a patient using an implanted neurostimulating device. Such method employs selective application of electrical signals to a predetermined location on the nerve to alter the activity of the nerve and cause dilation of a coronary artery in the patient, which in turn provides complete or partial relief of chest pain or deters the onset of such pain.

The invention provides a method for alleviating pain associated with neuromuscular or skeletal injury or inflammation by controlled and directed delivery of one or more biological response modifiers to inhibit the inflammatory response which ultimately causes acute or chronic pain. Controlled and directed delivery can be provided by implantable or infusion pumps, implantable controlled release devices, or by sustained release compositions comprising biological response modifiers.

A spine distraction implant alleviates pain associated with spinal stenosis and facet arthropathy by expanding the volume in the spine canal and/or neural foramen. The implant provides a spinal extension stop while allowing freedom of spinal flexion. An interspinous process implant with a selectably expandable spacer can be placed between adjacent spinous processes. a device implanted between the spinous processes of adjacent vertebrae of the spine can be used for relieving pain associated with the vertebrae and surrounding tissues and structures by maintaining and/or adding distraction between adjacent vertebrae. A tissue expander can be adapted to move from a first insertion position, for ease of implantation between spinous processes, to a second retention position that prevents displacement of the implant. An embodiment of a system can include an implant having a spacer with a thickness and a wing, wherein a first configuration of the wing has a first height substantially similar to the thickness and wherein the wing is adapted to be selectably arranged in a second configuration such that the wing has a second height greater than the first height. A periphery of the implant has a shape generally conformal with a shape of an inner surface of a cannula and a cross-sectional diameter smaller than an inner diameter of the cannula. The cannula is inserted such that a proximal end of the cannula is arranged between the adjacent spinous processes. The implant is then urged into position between the adjacent spinous processes by way of the cannula, and subsequently arranged in a second configuration to fix the implant in position.

The present disclosure provides enteric coated capsules and orally dissolving films comprising non-steroidal anti-inflammatory drugs and acid inhibitors, as well as methods of treating treatment humans for pain and/or inflammation while reducing gastrointestinal side effects.